Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may predict cancer treatment success

NCT ID NCT04056247

Knowledge-focused Sponsor: OncoHost Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to create a tool that can predict whether a cancer patient will benefit from their prescribed therapy. Researchers are analyzing blood samples from 10,000 people with advanced lung cancer or melanoma before and during treatment. The goal is to develop an algorithm that helps doctors choose the most effective treatment for each patient.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 10,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2019

Expected to finish

Oct 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

1. Stage IV NSCLC patients treated with ICI or a combination of ICI and chemotherapy in any line of treatment, or with chemotherapy as a first line treatment. 2. Stage III unresectable NSCLC patients treated with ICI therapy or ICI in combination with chemotherapy. 3. Stage IV malignant melanoma patients treated with any regimen that includes ICI therapy as a monotherapy or in combination with targeted therapy in any line of treatment. In specific sites, Stage IV melanoma patients treated with targeted therapy (as a reference population). 4. Stage IIIb-d malignant melanoma patients treated with any regimen that includes ICI therapy as monotherapy or in combination with targeted therapy as adjuvant therapy. 5. Stage IV SCLC patients treated with any regimen of ICI, chemotherapy or combination of ICI and chemotherapy in any line of treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria * Provision of informed consent prior to any study-specific procedures. * Male or female aged at least 18 years. * ECOG PS - 0/1-2 * Normal hematologic, renal and liver function: 1. Absolute neutrophil count higher than 1500/mm3 2. Platelets count higher than 100,000/mm3 3. haemoglobin higher than 9 g/dL 4. Creatinine concentration ≤1.4 mg/dL, or creatinine clearance higher than 40 mL/min 5. Total bilirubin lower than 1.5 mg/dL, ALT and AST levels ≤ 3 times above the upper normal limit. * At least one measurable lesion in order to enable the assessment of the response (except for stage IIIb-d malignant melanoma patients). Exclusion Criteria: * Concurrent and/or other active malignancy that has required systemic treatment within 2 years of first dose of study drug * Generalized impairment or mental incompetence that would render the patient unable to understand his/her participation in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stage III unresectable non-small cell lung cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stage III unresectable non-small cell lung cancer Stage IIIB-D malignant melanoma Stage IV malignant melanoma Stage IV non-small cell lung cancer Stage IV small cell lung cancer

Contacts and locations

Locations

  • 044 Hospital Universitario Virgen Macarena

    Seville, Spain

  • 151-Christus Health St. Michael

    Texarkana, Texas, 75503, United States

  • Aberdeen Royal Infirmary

    Aberdeen, United Kingdom

  • Asklepois

    Gauting, 82131, Germany

  • Assuta Medical Cetner

    Tel Aviv, Israel

  • Barzilai Medical Center

    Ashkelon, Israel

  • Birmingham VAHCS

    Birmingham, Alabama, 35233, United States

  • Bnai Zion Medical Center

    Haifa, Israel

  • Bradford Teaching Hospitals

    Bradford, BD9 6RJ, United Kingdom

  • Cheltenham General Hospital

    Cheltenham, United Kingdom

  • Florida Cancer Specialist and Research Institute

    Orlando, Florida, 32827, United States

  • Hadassah Medcial Center

    Jerusalem, Israel

  • Haemek Medical Center

    Afula, Israel

  • Helen Nassif Community Cancer Center

    Cedar Rapids, Iowa, 52403, United States

  • Kaplan Medical Center

    Rehovot, Israel

  • Lister Hospital

    Stevenage, United Kingdom

  • Mayo Clinic

    Jacksonville, Florida, 32224, United States

  • Meir medical center

    Kfar Saba, Israel

  • Michael E. Debakey VA Medical Center

    Houston, Texas, 77030, United States

  • Mount Vernon Cancer Centre

    Northwood, United Kingdom

  • Northwest Community Healthcare

    Rolling Meadows, Illinois, 60008, United States

  • Protean Biodiagnosics

    Orlando, Florida, 32827, United States

  • Rabin Medical Center

    Petah Tikva, Israel

  • Rambam Medical Center

    Haifa, Israel

  • Roswell Park

    Buffalo, New York, 14263, United States

  • Royal Bournemouth General Hospital

    Bournemouth, United Kingdom

  • Rutgers Cancer Institute

    New Brunswick, New Jersey, 08903, United States

  • Shamir Medical Center

    Be’er Ya‘aqov, Israel

  • Sheba Medical Center

    Tel Aviv, Israel

  • Sheba medical center

    Tel Litwinsky, Israel

  • Soroka Medical Center

    Beersheba, Israel

  • Sourasky Medical Center

    Tel Aviv, Israel

  • South Tyneside

    South Shields, NE34 0PL, United Kingdom

  • Sunderland Royal Hospital

    Sunderland, SR4 7TP, United Kingdom

  • Swansea Bay UHB Singleton Hospital

    Swansea, United Kingdom

  • The Shrewsbury and Telford Hospital

    Shrewsbury, United Kingdom

  • Thoraxklinik Heidelberg gGmbH

    Heidelberg, 69126, Germany

  • Torbay Hospital

    Torquay, United Kingdom

  • University of Miami

    Miami, Florida, 33136, United States

  • West Clinic

    Germantown, Tennessee, 38138, United States

  • Withybush Hospital

    Haverfordwest, SA61 2PZ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.